NCT00147511

Brief Summary

To assess the onset of action of linezolid

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
118

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2003

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2003

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2005

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 2, 2005

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 7, 2005

Completed
Last Updated

May 10, 2011

Status Verified

May 1, 2011

First QC Date

September 2, 2005

Last Update Submit

May 9, 2011

Conditions

Gram-Positive Bacterial InfectionsSkin and Connective Tissue Diseases

Outcome Measures

Primary Outcomes (1)

  • Time to defervescence

Secondary Outcomes (1)

  • Reduction of CRP levels Reduction of leucocyte count

Interventions

linezolidDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • suspected grampositive infection
  • fever \> 38 C

You may not qualify if:

  • Infections to be treated successfully by surgical procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Gram-Positive Bacterial InfectionsSkin and Connective Tissue Diseases

Interventions

Linezolid

Condition Hierarchy (Ancestors)

Bacterial InfectionsBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

AcetamidesAmidesOrganic ChemicalsAcetatesAcids, AcyclicCarboxylic AcidsOxazolidinonesOxazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 2, 2005

First Posted

September 7, 2005

Study Start

June 1, 2003

Study Completion

June 1, 2005

Last Updated

May 10, 2011

Record last verified: 2011-05